Loading...
Market
What type of regulatory action will Haleon face from the FDA related to its product claims by December 31, 2024?
2
Resolution / Starting Odds
Warning letter • 25%
Product recall • 25%
Monetary fine • 25%
No action • 25%
FDA announcements and news reports
Story
Robitussin Maker Settles $4.5 Million Lawsuit Over 'Non-Drowsy' Claim
Jul 22, 2024, 08:49 PM
The maker of Robitussin, Haleon, has settled a consumer lawsuit that claimed its 'non-drowsy' cough and flu medicine causes drowsiness. As part of the settlement, Haleon agreed to pay $4.5 million and remove the 'non-drowsy' claim from its packaging and marketing. The settlement covers Robitussin purchasers from February 16, 2016, to the present.
View original story
Similar markets
No action taken • 25%
Fine imposed • 25%
Production halted • 25%
Other • 25%
No action taken • 25%
Fines imposed • 25%
Production halted • 25%
Other • 25%
Yes • 50%
No • 50%
Warning letter only • 25%
Product recall • 25%
Fines imposed • 25%
Other actions • 25%
Issue warning • 33%
Initiate legal action • 33%
No action taken • 33%
No action taken • 25%
Warning issued • 25%
Fine imposed • 25%
Other sanctions • 25%
FDA • 25%
EMA • 25%
MHRA • 25%
Other • 25%
Approval in another major market • 25%
Rejection in another major market • 25%
Reapplication in the EU • 25%
No major decision • 25%